Navigation Links
Dana-Farber receive $5.6 million grant to develop rapid countermeasures to infectious agents
Date:1/18/2011

BOSTON--Researchers at Dana-Farber Cancer Institute have received a $5.6 million grant from the Defense Advanced Research Projects Agency (DARPA) and the Army Research Office (ARO) to develop transient immunity against known, unknown, naturally occurring, or engineered disease-causing pathogens. The ultimate goal is to develop a viable countermeasure to an unknown pathogen within seven days of receiving it in a laboratory.

Wayne A. Marasco, MD, PhD, of the Department of Cancer Immunology and AIDS at Dana-Farber and an associate professor of Medicine at Harvard Medical School, is the project's principal investigator.

Since the mid 1990's, DARPA's Defense Sciences Office has pioneered advances across the full spectrum of bio-warfare defense needs, including the development of advanced diagnostics and medical therapies that are active against an entire range of infectious agents.

"This grant will support revolutionary advances in rapid response to naturally evolving and engineered pathogens," says Marasco. "DARPA has issued a challenge to develop a treatment to unknown threats in just seven days, and we are excited about the opportunity to meet this challenge."

Disease-causing pathogens can be spread through natural and intentional means. Factors responsible for the increase in newly emerging and re-emerging pathogens include increased animal-human interface, increased population densities and international travel, climate change as it affects migration of animals such as birds, some of which could be disease carriers and the narrowing of genetic diversity among food animal stocks.

In addition, the proliferation of genetic engineering technologies that can be easily redirected from beneficent to offensive purposes, and the covert biological sabotage of food animals are all great biodefense concerns.

"In the past, medical responses to large-scale disease outbreaks have been very slow," said Marasco. "Often it has taken many months to years to research and create medicines or vaccines, time barriers that often result in loss of life. This program gives us an opportunity to very rapidly provide ways to prevent infection and extend survival until long-term solutions are available."

Marasco will direct an international team of leading scientists and businesses engaged in the study of pathogen detection, screening, and therapeutic formulation and manufacturing. The team will pursue two parallel paths toward the program goals: First, to rapidly select broadly neutralizing phage antibodies for direct use as therapeutics for microbial infection; and Second, to investigate selective anti-idiotypic stimulation of B-cell precursors leading to secretion of antibodies with broad-spectrum, natural, anti-microbial activity.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Related biology news :

1. Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test
2. Dana-Farber and sanofi-aventis establish cancer research alliance
3. Wistar Institute researcher receives New Innovator award from NIH
4. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
5. Kount Receives Patent for Device Fingerprinting
6. American College of Medical Genetics receives $13.5M NIH contract
7. Carnegie Mellon to receive $900,000 from EPA for brownfields research
8. Penn State receives new NASA astrobiology grant
9. Salk scientist Fred H. Gage to receive the Keio Medical Science Prize
10. Global Viral Forecasting Initiative receives $11M to implement pandemic early warning system
11. Vidaza receives positve opinion from European CHMP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new ... - 2022," projects that the global biometric technology market is expected to generate revenue ... 2022. Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... January 11, 2017 , ... With sepsis claiming ... more than $23.7 billion, healthcare systems are looking to provide better and ... common sepsis-causing pathogens are bacteria and the yeast pathogen Candida, which can lead ...
(Date:1/11/2017)... ... January 11, 2017 , ... IsoPlexis ... response analysis platform to measure the proteomic function of individual cells in patients, ... Research (SBIR) grant from the National Institute on Aging of the National Institutes ...
(Date:1/11/2017)... ... January 11, 2017 , ... Back pain relief technology ... Shots and No Surgery for positive back pain relief for WAR members. , This ... worldwide and could be life changing for millions suffering from chronic back pain. , ...
(Date:1/11/2017)... 11, 2017 AnaptysBio, Inc., a clinical-stage ... on unmet medical needs in inflammation, today announced ... chief financial officer.  Mr. Piscitelli will play a ... as overseeing the company,s accounting and SEC reporting ... welcome Dominic to the senior management team at ...
Breaking Biology Technology: